Pediatric Infectious Disease

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  6 (2024)
Volume  5 (2023)
Volume  4 (2022)
Volume  3 (2021)
Volume  2 (2020)
Volume  1 (2019)
Related articles

VOLUME 2 , ISSUE 1 ( January-March, 2020 ) > List of Articles

Immunization Dialogue

Dengue Vaccines: An Update

Srinivas G Kasi

Citation Information : Kasi SG. Dengue Vaccines: An Update. Pediatr Inf Dis 2020; 2 (1):32-33.

DOI: 10.5005/jp-journals-10081-1248

License: CC BY-NC 4.0

Published Online: 21-10-2020

Copyright Statement:  Copyright © 2020; The Author(s).


Abstract

Dengvaxia is a live recombinant tetravalent dengue vaccine, licensed from December 2015 for individuals from endemic area in the age-group of 9–45 years. This update gives the recent recommendations for dengue vaccination and also provides information on the newer dengue vaccines in the pipeline.

PDF Share
  1. http://www.who.int/vaccine_safety/committee/GACVS-StatementonDengvaxia-CYD-TDV/en/.
  2. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–1365. DOI: 10.1016/S0140-6736(14)61060-6.
  3. Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015;372(2):113–123. DOI: 10.1056/NEJMoa1411037.
  4. Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015;373:1195–1206. DOI: 10.1056/NEJMoa1506223.
  5. Dengue vaccine: WHO position paper – July 2016. No 30, 2016, 91, 349–364 http://www.who.int/wer.
  6. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med 2018;379(4): 327–340. DOI: 10.1056/NEJMoa1800820.
  7. Dengue vaccine: WHO position paper – September 2018. No 36, 2018, 93, 457–476. http://www.who.int/wer.
  8. https://www.who.int/research-observatory/monitoring/processes/health_products_September_2018/en/.
  9. Swaminathan S, Khanna N. Dengue vaccine development: Global and Indian scenarios. Int J Infect Dis 2019;84:S80–S86. DOI: 10.1016/j.ijid.2019.01.029.
  10. Biswal S, Reynales H, Saez-Llorens X, et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 2019;381:2009–2019. DOI: 10.1056/NEJMoa1903869.
  11. Diaz C, Lin L, Martinez LJ, et al. Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico. Am J Trop Med Hyg 2018;98(5):1435–1443. DOI: 10.4269/ajtmh.17-0627.
  12. Schmidt AC, Lin L, Martinez LJ, et al. Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States. Am J Trop Med Hyg 2017;96(6):1325–1337. DOI: 10.4269/ajtmh.16-0634.
  13. https://docs.google.com/spreadsheets/d/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM/pubhtml.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.